Calcitonin gene-related peptide / Akela Pharma - LARVOL DELTA

Comparing Patient-Reported Outcomes in Patients Using CGRP Antagonists or OnabotulinumtoxinA for Chronic Migraine (AMCP 2019) - "Sponsor: None; BACKGROUND: Calcitonin gene-related peptide (CGRP) antagonists are a new drug class indicated for chronic migraine prevention...Patients were identified if they were on a CGRP antagonist (CGRP; including erenumab-aooe, galcanezumab-gnlm, and fremanezumab-vfrm) or on onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis from 1/1/2018 through 12/1/18... There was no difference between CGRP and ONA groups using PROs with at least a 50% reduction from baseline in MHD or HIT-6 class severity improvement. Patients in both groups experienced significant improvement in MHD and pain, but only the ONA group experienced decrease in migraine duration."

Clinical